Last Updated : October 16, 2023
Details
Generic Name:
liraglutide
Project Status:
Not filed
Therapeutic Area:
Diabetes Mellitus, Type 2 (pediatric)
Manufacturer:
Novo Nordisk Canada Inc.
Brand Name:
Victoza
Project Line:
Reimbursement Review
Project Number:
N/A
Manufacturer Requested Reimbursement Criteria1:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Submission Type:
Non Submission
Indications:
In adolescents and children aged 10 years and above with type 2 diabetes, Victoza is indicated as an adjunct to metformin with or without basal insulin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 16, 2023